Literature DB >> 19707061

Perspective: Disclosing hidden sources of funding.

David B Resnik1.   

Abstract

In this article, the author discusses ethical and policy issues related to the disclosure of hidden sources of funding in research. The author argues that authors have an ethical obligation to disclose hidden sources of funding and that journals should adopt policies to enforce this obligation. Journal policies should require disclosure of hidden sources of funding that authors know about and that have a direct relation to their research. To stimulate this discussion, the author describes a recent case: investigators who conducted a lung cancer screening study had received funding from a private foundation that was supported by a tobacco company, but they did not disclose this relationship to the journal. Investigators and journal editors must be prepared to deal with these issues in a manner that promotes honesty, transparency, fairness, and accountability in research. The development of well-defined, reasonable policies pertaining to hidden sources of funding can be a step in this direction.

Entities:  

Mesh:

Year:  2009        PMID: 19707061      PMCID: PMC3954610          DOI: 10.1097/ACM.0b013e3181b18835

Source DB:  PubMed          Journal:  Acad Med        ISSN: 1040-2446            Impact factor:   6.893


  6 in total

1.  Financial associations of authors.

Authors:  Jeffrey M Drazen; Gregory D Curfman
Journal:  N Engl J Med       Date:  2002-06-13       Impact factor: 91.245

2.  A comparison of conflict of interest policies at peer-reviewed journals in different scientific disciplines.

Authors:  Jessica S Ancker; Annette Flanagin
Journal:  Sci Eng Ethics       Date:  2007-06-07       Impact factor: 3.525

3.  Full disclosure and the funding of biomedical research.

Authors:  Robert S Schwartz; Gregory D Curfman; Stephen Morrissey; Jeffrey M Drazen
Journal:  N Engl J Med       Date:  2008-04-02       Impact factor: 91.245

4.  Clarification of funding of early lung cancer study.

Authors:  Claudia Henschke
Journal:  N Engl J Med       Date:  2008-04-02       Impact factor: 91.245

5.  Survival of patients with stage I lung cancer detected on CT screening.

Authors:  Claudia I Henschke; David F Yankelevitz; Daniel M Libby; Mark W Pasmantier; James P Smith; Olli S Miettinen
Journal:  N Engl J Med       Date:  2006-10-26       Impact factor: 91.245

6.  Computed tomography screening and lung cancer outcomes.

Authors:  Peter B Bach; James R Jett; Ugo Pastorino; Melvyn S Tockman; Stephen J Swensen; Colin B Begg
Journal:  JAMA       Date:  2007-03-07       Impact factor: 56.272

  6 in total
  3 in total

1.  Industry involvement and baseline assumptions of cost-effectiveness analyses: diagnostic accuracy of the Papanicolaou test.

Authors:  Nikolaos P Polyzos; Antonis Valachis; Davide Mauri; John P A Ioannidis
Journal:  CMAJ       Date:  2011-03-14       Impact factor: 8.262

2.  Taking financial relationships into account when assessing research.

Authors:  David B Resnik; Kevin C Elliott
Journal:  Account Res       Date:  2013       Impact factor: 2.622

3.  The Sunshine Act: commercial conflicts of interest and the limits of transparency.

Authors:  Mark Wilson
Journal:  Open Med       Date:  2014-01-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.